细胞因子释放综合征的管理：新兴抗原特异性T细胞衔接免疫疗法的最新进展 - Suppr

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

作者信息

Khadka Roman H, Sakemura Reona, Kenderian Saad S, Johnson Aaron J

机构信息

Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Department of Immunology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

出版信息

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4.

DOI:10.2217/imt-2019-0074

PMID:31161844

Abstract

摘要

相似文献

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4.

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol. 2019 Mar;12(3):195-205. doi: 10.1080/17474086.2019.1585238. Epub 2019 Mar 18.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.

Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.

Int J Mol Sci. 2021 Jul 17;22(14):7652. doi: 10.3390/ijms22147652.

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127. doi: 10.1016/j.bbmt.2018.12.756. Epub 2018 Dec 23.

Management Principles Associated With Cytokine Release Syndrome.

Semin Oncol Nurs. 2019 Oct;35(5):150931. doi: 10.1016/j.soncn.2019.08.010. Epub 2019 Aug 31.

Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.

Clin Cancer Res. 2019 Jan 1;25(1):29-34. doi: 10.1158/1078-0432.CCR-18-1379. Epub 2018 Oct 15.

T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.

Heart Fail Clin. 2022 Jul;18(3):443-454. doi: 10.1016/j.hfc.2022.02.008.

Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.

Front Immunol. 2023 May 25;14:1190379. doi: 10.3389/fimmu.2023.1190379. eCollection 2023.

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000742.

引用本文的文献

Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.

J Transl Med. 2025 Jul 25;23(1):834. doi: 10.1186/s12967-025-06857-w.

Combined IVIG and High-Dose Systemic Corticosteroids for the Management of Pembrolizumab-Induced Cytokine Release Syndrome in Lung Adenocarcinoma.

Respirol Case Rep. 2025 May 19;13(5):e70215. doi: 10.1002/rcr2.70215. eCollection 2025 May.

CAR-T therapy dilemma and innovative design strategies for next generation.

Cell Death Dis. 2025 Mar 27;16(1):211. doi: 10.1038/s41419-025-07454-x.

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.

Clin Pharmacokinet. 2024 Dec;63(12):1757-1768. doi: 10.1007/s40262-024-01451-7. Epub 2024 Nov 26.

PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies.

Mol Imaging. 2024 May 29;23:15353508241257924. doi: 10.1177/15353508241257924. eCollection 2024 Jan-Dec.

Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions.

Front Pharmacol. 2024 Apr 10;15:1383000. doi: 10.3389/fphar.2024.1383000. eCollection 2024.

A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.

Cancer Immunol Immunother. 2024 Apr 20;73(6):107. doi: 10.1007/s00262-024-03680-y.

Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide.

Cells. 2023 Aug 11;12(16):2049. doi: 10.3390/cells12162049.

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.

Nat Cancer. 2023 Apr;4(4):485-501. doi: 10.1038/s43018-023-00536-9. Epub 2023 Mar 30.

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.

J Vis Exp. 2023 Feb 10(192). doi: 10.3791/64535.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

作者信息

机构信息

出版信息

相似文献

引用本文的文献